|
1
|
Peña-Guerrero J, Fernández-Rubio C, Burguete-Mikeo A, El-Dirany R, García-Sosa AT, Nguewa P. Discovery and Validation of Lmj_04_BRCT Domain, a Novel Therapeutic Target: Identification of Candidate Drugs for Leishmaniasis. Int J Mol Sci 2021; 22:ijms221910493. [PMID: 34638841 PMCID: PMC8508789 DOI: 10.3390/ijms221910493] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2021] [Revised: 09/13/2021] [Accepted: 09/23/2021] [Indexed: 01/09/2023] Open
Abstract
Since many of the currently available antileishmanial treatments exhibit toxicity, low effectiveness, and resistance, search and validation of new therapeutic targets allowing the development of innovative drugs have become a worldwide priority. This work presents a structure-based drug discovery strategy to validate the Lmj_04_BRCT domain as a novel therapeutic target in Leishmania spp. The structure of this domain was explored using homology modeling, virtual screening, and molecular dynamics studies. Candidate compounds were validated in vitro using promastigotes of Leishmania major, L. amazonensis, and L. infantum, as well as primary mouse macrophages infected with L. major. The novel inhibitor CPE2 emerged as the most active of a group of compounds against Leishmania, being able to significantly reduce the viability of promastigotes. CPE2 was also active against the intracellular forms of the parasites and significantly reduced parasite burden in murine macrophages without exhibiting toxicity in host cells. Furthermore, L. major promastigotes treated with CPE2 showed significant lower expression levels of several genes (α-tubulin, Cyclin CYCA, and Yip1) related to proliferation and treatment resistance. Our in silico and in vitro studies suggest that the Lmj_04_BRCT domain and its here disclosed inhibitors are new potential therapeutic options against leishmaniasis.
Collapse
Affiliation(s)
- José Peña-Guerrero
- Department of Microbiology and Parasitology, ISTUN Instituto de Salud Tropical, IdiSNA, Instituto de Investigación Sanitaria de Navarra, Universidad de Navarra, E-31008 Pamplona, Spain; (J.P.-G.); (C.F.-R.); (A.B.-M.); (R.E.-D.)
| | - Celia Fernández-Rubio
- Department of Microbiology and Parasitology, ISTUN Instituto de Salud Tropical, IdiSNA, Instituto de Investigación Sanitaria de Navarra, Universidad de Navarra, E-31008 Pamplona, Spain; (J.P.-G.); (C.F.-R.); (A.B.-M.); (R.E.-D.)
| | - Aroia Burguete-Mikeo
- Department of Microbiology and Parasitology, ISTUN Instituto de Salud Tropical, IdiSNA, Instituto de Investigación Sanitaria de Navarra, Universidad de Navarra, E-31008 Pamplona, Spain; (J.P.-G.); (C.F.-R.); (A.B.-M.); (R.E.-D.)
| | - Rima El-Dirany
- Department of Microbiology and Parasitology, ISTUN Instituto de Salud Tropical, IdiSNA, Instituto de Investigación Sanitaria de Navarra, Universidad de Navarra, E-31008 Pamplona, Spain; (J.P.-G.); (C.F.-R.); (A.B.-M.); (R.E.-D.)
| | - Alfonso T. García-Sosa
- Department of Molecular Technology, Institute of Chemistry, University of Tartu, 50411 Tartu, Estonia
- Correspondence: (A.T.G.-S.); (P.N.); Tel.: +372-737-5270 (A.T.G.-S.); +34-948-425-600 (ext. 6434) (P.N.)
| | - Paul Nguewa
- Department of Microbiology and Parasitology, ISTUN Instituto de Salud Tropical, IdiSNA, Instituto de Investigación Sanitaria de Navarra, Universidad de Navarra, E-31008 Pamplona, Spain; (J.P.-G.); (C.F.-R.); (A.B.-M.); (R.E.-D.)
- Correspondence: (A.T.G.-S.); (P.N.); Tel.: +372-737-5270 (A.T.G.-S.); +34-948-425-600 (ext. 6434) (P.N.)
| |
Collapse
|
|
2
|
Lu L, Fong CHY, Zhang AJ, Wu WL, Li IC, Lee ACY, Dissanayake TK, Chen L, Hung IFN, Chan KH, Chu H, Kok KH, Yuen KY, To KKW. Repurposing of Miltefosine as an Adjuvant for Influenza Vaccine. Vaccines (Basel) 2020; 8:vaccines8040754. [PMID: 33322574 PMCID: PMC7768360 DOI: 10.3390/vaccines8040754] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2020] [Revised: 12/07/2020] [Accepted: 12/09/2020] [Indexed: 12/11/2022] Open
Abstract
We previously reported that topical imiquimod can improve the immunogenicity of the influenza vaccine. This study investigated another FDA-approved drug, miltefosine (MTF), as a vaccine adjuvant. Mice immunized with an influenza vaccine with or without MTF adjuvant were challenged by a lethal dose of influenza virus 3 or 7 days after vaccination. Survival, body weight, antibody response, histopathological changes, viral loads, cytokine levels, and T cell frequencies were compared. The MTF-adjuvanted vaccine (MTF-VAC) group had a significantly better survival rate than the vaccine-only (VAC) group, when administered 3 days (80% vs. 26.7%, p = 0.0063) or 7 days (96% vs. 65%, p = 0.0041) before influenza virus challenge. Lung damage was significantly ameliorated in the MTF-VAC group. Antibody response was significantly augmented in the MTF-VAC group against both homologous and heterologous influenza strains. There was a greater T follicular helper cell (TFH) response and an enhanced germinal center (GC) reaction in the MTF-VAC group. MTF-VAC also induced both TH1 and TH2 antigen-specific cytokine responses. MTF improved the efficacy of the influenza vaccine against homologous and heterologous viruses by improving the TFH and antibody responses. Miltefosine may also be used for other vaccines, including the upcoming vaccines for COVID-19.
Collapse
Affiliation(s)
- Lu Lu
- State Key Laboratory for Emerging Infectious Diseases, Department of Microbiology, Carol Yu Centre for Infection, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China; (L.L.); (C.H.-Y.F.); (A.J.Z.); (W.-L.W.); (I.C.L.); (A.C.-Y.L.); (T.K.D.); (L.C.); (K.-H.C.); (H.C.); (K.-H.K.); (K.-Y.Y.)
| | - Carol Ho-Yan Fong
- State Key Laboratory for Emerging Infectious Diseases, Department of Microbiology, Carol Yu Centre for Infection, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China; (L.L.); (C.H.-Y.F.); (A.J.Z.); (W.-L.W.); (I.C.L.); (A.C.-Y.L.); (T.K.D.); (L.C.); (K.-H.C.); (H.C.); (K.-H.K.); (K.-Y.Y.)
| | - Anna Jinxia Zhang
- State Key Laboratory for Emerging Infectious Diseases, Department of Microbiology, Carol Yu Centre for Infection, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China; (L.L.); (C.H.-Y.F.); (A.J.Z.); (W.-L.W.); (I.C.L.); (A.C.-Y.L.); (T.K.D.); (L.C.); (K.-H.C.); (H.C.); (K.-H.K.); (K.-Y.Y.)
| | - Wai-Lan Wu
- State Key Laboratory for Emerging Infectious Diseases, Department of Microbiology, Carol Yu Centre for Infection, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China; (L.L.); (C.H.-Y.F.); (A.J.Z.); (W.-L.W.); (I.C.L.); (A.C.-Y.L.); (T.K.D.); (L.C.); (K.-H.C.); (H.C.); (K.-H.K.); (K.-Y.Y.)
| | - Iris Can Li
- State Key Laboratory for Emerging Infectious Diseases, Department of Microbiology, Carol Yu Centre for Infection, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China; (L.L.); (C.H.-Y.F.); (A.J.Z.); (W.-L.W.); (I.C.L.); (A.C.-Y.L.); (T.K.D.); (L.C.); (K.-H.C.); (H.C.); (K.-H.K.); (K.-Y.Y.)
| | - Andrew Chak-Yiu Lee
- State Key Laboratory for Emerging Infectious Diseases, Department of Microbiology, Carol Yu Centre for Infection, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China; (L.L.); (C.H.-Y.F.); (A.J.Z.); (W.-L.W.); (I.C.L.); (A.C.-Y.L.); (T.K.D.); (L.C.); (K.-H.C.); (H.C.); (K.-H.K.); (K.-Y.Y.)
| | - Thrimendra Kaushika Dissanayake
- State Key Laboratory for Emerging Infectious Diseases, Department of Microbiology, Carol Yu Centre for Infection, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China; (L.L.); (C.H.-Y.F.); (A.J.Z.); (W.-L.W.); (I.C.L.); (A.C.-Y.L.); (T.K.D.); (L.C.); (K.-H.C.); (H.C.); (K.-H.K.); (K.-Y.Y.)
| | - Linlei Chen
- State Key Laboratory for Emerging Infectious Diseases, Department of Microbiology, Carol Yu Centre for Infection, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China; (L.L.); (C.H.-Y.F.); (A.J.Z.); (W.-L.W.); (I.C.L.); (A.C.-Y.L.); (T.K.D.); (L.C.); (K.-H.C.); (H.C.); (K.-H.K.); (K.-Y.Y.)
| | - Ivan Fan-Ngai Hung
- Department of Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China;
| | - Kwok-Hung Chan
- State Key Laboratory for Emerging Infectious Diseases, Department of Microbiology, Carol Yu Centre for Infection, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China; (L.L.); (C.H.-Y.F.); (A.J.Z.); (W.-L.W.); (I.C.L.); (A.C.-Y.L.); (T.K.D.); (L.C.); (K.-H.C.); (H.C.); (K.-H.K.); (K.-Y.Y.)
| | - Hin Chu
- State Key Laboratory for Emerging Infectious Diseases, Department of Microbiology, Carol Yu Centre for Infection, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China; (L.L.); (C.H.-Y.F.); (A.J.Z.); (W.-L.W.); (I.C.L.); (A.C.-Y.L.); (T.K.D.); (L.C.); (K.-H.C.); (H.C.); (K.-H.K.); (K.-Y.Y.)
| | - Kin-Hang Kok
- State Key Laboratory for Emerging Infectious Diseases, Department of Microbiology, Carol Yu Centre for Infection, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China; (L.L.); (C.H.-Y.F.); (A.J.Z.); (W.-L.W.); (I.C.L.); (A.C.-Y.L.); (T.K.D.); (L.C.); (K.-H.C.); (H.C.); (K.-H.K.); (K.-Y.Y.)
| | - Kwok-Yung Yuen
- State Key Laboratory for Emerging Infectious Diseases, Department of Microbiology, Carol Yu Centre for Infection, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China; (L.L.); (C.H.-Y.F.); (A.J.Z.); (W.-L.W.); (I.C.L.); (A.C.-Y.L.); (T.K.D.); (L.C.); (K.-H.C.); (H.C.); (K.-H.K.); (K.-Y.Y.)
- Department of Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China;
| | - Kelvin Kai-Wang To
- State Key Laboratory for Emerging Infectious Diseases, Department of Microbiology, Carol Yu Centre for Infection, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China; (L.L.); (C.H.-Y.F.); (A.J.Z.); (W.-L.W.); (I.C.L.); (A.C.-Y.L.); (T.K.D.); (L.C.); (K.-H.C.); (H.C.); (K.-H.K.); (K.-Y.Y.)
- Department of Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China;
- Correspondence:
| |
Collapse
|
|
3
|
Marquet S, Bucheton B, Reymond C, Argiro L, El-Safi SH, Kheir MM, Desvignes JP, Béroud C, Mergani A, Hammad A, Dessein AJ. Exome Sequencing Identifies Two Variants of the Alkylglycerol Monooxygenase Gene as a Cause of Relapses in Visceral Leishmaniasis in Children, in Sudan. J Infect Dis 2017; 216:22-28. [PMID: 28586473 DOI: 10.1093/infdis/jix277] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2017] [Accepted: 06/02/2017] [Indexed: 01/01/2023] Open
Abstract
Background Visceral leishmaniasis (kala-azar, KA) is the most severe form of leishmaniasis, characterized by fever, weight loss, hepatosplenomegaly, and lymphadenopathy. During an outbreak of KA in Babar El Fugara (Sudan), 5.7% of cured patients displayed relapses, with familial clustering in half the cases. Methods We performed whole-exome sequencing on 10 relapsing individuals and 11 controls from 5 nuclear families. Results Rare homozygous and compound-heterozygous nonsense (c.1213C > T, rs139309795, p.Arg405*) and missense (c.701A > G, rs143439626, p.Lys234Arg) mutations of the alkylglycerol monooxygenase (AGMO) gene were associated with KA relapse in 3 families. Sequencing in additional family members confirmed the segregation of these mutations with relapse and revealed an autosomal dominant mode of transmission. These mutations were detected heterozygous in 2 subjects among 100 unrelated individuals with KA who never relapsed after cure, suggesting incomplete penetrance of AGMO deficiency. AGMO is expressed in hematopoietic cells, and is strongly expressed in the liver. AGMO modulates PAF production by mouse macrophages, suggesting that it may act through the PAF/PAF receptor pathway previously shown to have anti-Leishmania activity. Conclusions This is the first demonstration that relapses after a first episode of KA are due to differences in human genetic susceptibility and not to modifications of parasite pathogenicity.
Collapse
Affiliation(s)
- Sandrine Marquet
- INSERM UMR906, GIMP, Labex ParaFrap, Aix-Marseille University, Marseille
| | - Bruno Bucheton
- INSERM UMR906, GIMP, Labex ParaFrap, Aix-Marseille University, Marseille.,Institut de Recherche pour le Développement, Unité Mixte de Recherche IRD-CIRAD 177, Campus International de Baillarguet, Montpellier, France
| | - Camille Reymond
- INSERM UMR906, GIMP, Labex ParaFrap, Aix-Marseille University, Marseille
| | - Laurent Argiro
- INSERM UMR906, GIMP, Labex ParaFrap, Aix-Marseille University, Marseille
| | - Sayda Hassan El-Safi
- Department of Microbiology and Parasitology, Faculty of Medicine, University of Khartoum, Khartoum, Sudan
| | - Musa Mohamed Kheir
- Department of Microbiology and Parasitology, Faculty of Medicine, University of Khartoum, Khartoum, Sudan
| | | | - Christophe Béroud
- INSERM UMR910, GMGF, Aix-Marseille University.,AP-HM, Département de Génétique Médicale, Hôpital Timone Enfants, Marseille, France
| | - Adil Mergani
- College of Applied Medical Sciences, Taif University, Turabah, Saudi Arabia
| | - Awad Hammad
- Department of Microbiology and Parasitology, Faculty of Medicine, University of Khartoum, Khartoum, Sudan
| | - Alain J Dessein
- INSERM UMR906, GIMP, Labex ParaFrap, Aix-Marseille University, Marseille
| |
Collapse
|
|
4
|
Gangalum PR, de Castro W, Vieira LQ, Dey R, Rivas L, Singh S, Majumdar S, Saha B. Platelet-Activating Factor Receptor Contributes to Antileishmanial Function of Miltefosine. THE JOURNAL OF IMMUNOLOGY 2015; 194:5961-7. [DOI: 10.4049/jimmunol.1401890] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/24/2014] [Accepted: 03/30/2015] [Indexed: 11/19/2022]
|
|
5
|
Garg R, Tremblay MJ. Miltefosine represses HIV-1 replication in human dendritic cell/T-cell cocultures partially by inducing secretion of type-I interferon. Virology 2012; 432:271-6. [DOI: 10.1016/j.virol.2012.05.032] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2012] [Revised: 05/07/2012] [Accepted: 05/24/2012] [Indexed: 10/28/2022]
|
|
6
|
Dorlo TPC, Balasegaram M, Beijnen JH, de Vries PJ. Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. J Antimicrob Chemother 2012; 67:2576-97. [PMID: 22833634 DOI: 10.1093/jac/dks275] [Citation(s) in RCA: 501] [Impact Index Per Article: 41.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Miltefosine is an alkylphosphocholine drug with demonstrated activity against various parasite species and cancer cells as well as some pathogenic bacteria and fungi. For 10 years it has been licensed in India for the treatment of visceral leishmaniasis (VL), a fatal neglected parasitic disease. It is the first and still the only oral drug that can be used to treat VL and cutaneous leishmaniasis (CL). The standard 28 day miltefosine monotherapy regimen is well tolerated, except for mild gastrointestinal side effects, although its teratogenic potential severely hampers its general use in the clinic and roll-out in national elimination programmes. The pharmacokinetics of miltefosine are mainly characterized by its long residence time in the body, resulting in extensive drug accumulation during treatment and long elimination half-lives. At the moment, different combination therapy strategies encompassing miltefosine are being tested in multiple controlled clinical trials in various geographical areas of endemicity, both in South Asia and East Africa. We here review the most salient pre-clinical and clinical pharmacological aspects of miltefosine, its mechanism of action against Leishmania parasites and other pathogens, and provide a systematic overview of the efficacy and safety data from all clinical trials of miltefosine, either alone or in combination, in the treatment of VL and CL.
Collapse
Affiliation(s)
- Thomas P C Dorlo
- Center for Tropical Medicine and Travel Medicine, Division of Infectious Diseases, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
| | | | | | | |
Collapse
|
|
7
|
Mukherjee AK, Gupta G, Adhikari A, Majumder S, Kar Mahapatra S, Bhattacharyya Majumdar S, Majumdar S. Miltefosine triggers a strong proinflammatory cytokine response during visceral leishmaniasis: Role of TLR4 and TLR9. Int Immunopharmacol 2012; 12:565-72. [DOI: 10.1016/j.intimp.2012.02.002] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2011] [Revised: 11/25/2011] [Accepted: 02/06/2012] [Indexed: 12/29/2022]
|
|
8
|
Khademvata S, Gharavi MJ, Yousefi E, Saki J. INOS and IFNγ Gene Expression in Leishmania major-Infected J774 Cells Treated With Miltefosine. INT J PHARMACOL 2011. [DOI: 10.3923/ijp.2011.843.849] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
|
9
|
Wadhone P, Maiti M, Agarwal R, Kamat V, Martin S, Saha B. Miltefosine promotes IFN-gamma-dominated anti-leishmanial immune response. JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 2009; 182:7146-54. [PMID: 19454711 DOI: 10.4049/jimmunol.0803859] [Citation(s) in RCA: 95] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/16/2023]
Abstract
Leishmania donovani, a protozoan parasite, resides and replicates as amastigotes within macrophages. The parasite inflicts the disease visceral leishmaniasis by suppressing host cell function. Neither a therapeutic vaccine nor an effective anti-leishmanial drug to reverse the immunosuppression is available. Although miltefosine (hexadecylphosphocholine or HPC) is a promising orally bioavailable anti-leishmanial drug, its efficacy is seriously compromised by contra-indications in pregnant women. Further rational redesigning of the drug requires studies on its mechanism of action, which is unknown at present. Because miltefosine is proposed to have immunomodulatory functions, we examined whether miltefosine exerts its anti-leishmanial functions by activating macrophages. We observed that miltefosine's anti-leishmanial function was significantly compromised in IFN-gamma-deficient macrophages suggesting the importance of endogenous IFN-gamma in miltefosine-induced anti-leishmanial functions of macrophages. Miltefosine induced IFN-gamma, neutralization of which reduced the anti-leishmanial functions of macrophages. IFN-gamma responsiveness is reduced in L. donovani-infected macrophages but is significantly restored by miltefosine, as it enhances IFN-gamma receptors and IFN-gamma induced STAT-1 phosphorylation but reduced activation of SHP-1, the phosphatase implicated in the down-regulation of STAT-1 phosphorylation. Miltefosine induced protein kinase C-dependent and PI3K-dependent p38MAP kinase phosphorylation and anti-leishmanial function. Miltefosine promotes p38MAP kinase-dependent anti-leishmanial functions and IL-12-dependent Th1 response. Leishmania donovani-infected macrophages induced Th2 response but miltefosine treatment reversed the response to Th1-type. Thus, our data define for the first time the mechanistic basis of host cell-dependent anti-leishmanial function of miltefosine.
Collapse
|
|
10
|
Gong YK, Mwale F, Wertheimer MR, Winnik FM. Promotion of U937 cell adhesion on polypropylene surfaces bearing phosphorylcholine functionalities. JOURNAL OF BIOMATERIALS SCIENCE-POLYMER EDITION 2005; 15:1423-34. [PMID: 15648572 DOI: 10.1163/1568562042368022] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Phosphorylcholine (PC) groups were grafted onto ammonia plasma-treated biaxially-oriented polypropylene (BOPP) surfaces, via (a) reductive amination of phosphorylcholine glyceraldehyde and (b) a two-step procedure involving the chemical amplification of surface amine groups with tris(2-aminoethyl amine) and subsequent reductive amination of phosphorylcholine glyceraldehyde. The occurrence of grafting was ascertained by X-ray photoelectron spectroscopy (XPS) and attenuated total reflectance Fourier-transform infrared (ATR-FT-IR) spectroscopy. The wettability of PC-modified surfaces was assessed by dynamic contact-angle measurements using the Wilhelmy plate method. Human U937 macrophages adhered and proliferated to a significantly larger extent on PC-modified surfaces, compared to unmodified or ammonia plasma-modified BOPP.
Collapse
Affiliation(s)
- Yong-Kuan Gong
- Department of Chemistry and Faculty of Pharmacy, University of Montreal, Montréal, Québec, Canada H3C 3J7
| | | | | | | |
Collapse
|
|
11
|
Gong YK, Luo L, Petit A, Zukor DJ, Huk OL, Antoniou J, Winnik FM, Mwale F. Adhesion of human U937 macrophages to phosphorylcholine-coated surfaces. ACTA ACUST UNITED AC 2004; 72:1-9. [PMID: 15529314 DOI: 10.1002/jbm.a.30135] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
A new type of amphiphilic phosphorylcholine (PC) polymer was used in this work to develop a cell culture surface that allows the attachment of U937 macrophages. The PC polymer was a random copolymer of N-isopropylacrylamide (45%), N-(phosphorylcholine)-N'-(ethylenedioxy-bis(ethyl)) acrylamide (41%), and the hydrophobic monomer N-(n-octadecyl) acrylamide (14%). Polypropylene (PP) films (1 cm2) were coated with the polymer solution by immersion. U937 macrophage suspensions were applied on PC polymer-coated surfaces and incubated for up to 72 h at 37 degrees C. While U937 cells did not adhere to PP, ammonia, nitrogen, or oxygen plasma-treated surfaces, they attached rapidly on PC-coated surfaces (< 1 h), proliferated, and stayed attached to the modified surface for at least 72 h, suggesting that unique features of the PC polymer, and the U937 macrophages, are responsible for the attachment of these cells. We compared the effect of Co2+ and Cr3+ ions on the expression of bone-resorbing cytokines (TNF-alpha, IL-6, IL-1beta) in U937 macrophages cultured on PC-coated surfaces to the response of U937 macrophages in suspension. Cytokine gene expression was analyzed by reverse transcription polymerase chain reaction (RT-PCR). Addition of Co2+ and Cr3+ ions led to a significant increased expression of TNF-alpha in both cultured and suspension cells. On the other hand, Co2+ and Cr3+ ions had a weak stimulatory effect or no effect on IL-1beta and IL-6, respectively, in both cultured and suspension cells. In conclusion, the use of PC polymer-modified surfaces might offer promising new opportunities for the culture of human U937 cells and may also point to the mechanism by which macrophages interact with lipid bilayers of biological membranes.
Collapse
Affiliation(s)
- Yong-Kuan Gong
- Department of Chemistry and Faculty of Pharmacy, University of Montreal, CP 6128, Succursale Centre Ville, Montreal, Quebec, H3C 3J7, Canada
| | | | | | | | | | | | | | | |
Collapse
|